Immunoassay Interference Blocker Market Segmented By Top Companies - Abcam plc, AMS Biotechnology (Europe) Limited, Aviva Systems Biology Corporation

Continual developments in the healthcare sector remain a catalyzing factor for improved research capabilities. Rapid investments in research and development to gain advancements in clinical diagnosis and the improve results of biochemical analysis. Constant clinical efforts towards improving disease diagnosis in a bid to offer effective patient care to individuals remains pivotal for healthcare professionals. Laboratory test results, including immunoassay results, influence about 70 percent of healthcare decisions. When healthcare decisions are built on inaccurate results owing to biotin interference, there is a risk of inappropriate and sometimes irreversible treatment.

Persistence Market Research (PMR) has conducted a detailed assessment of the immunoassay interference blocker involving a global market perspective on the acceptance of immunoassay interference blockers owing to growing prevalence of chronic diseases that create the need for effective and accurate clinical results. Factors supporting the demand growth such as continual technological advancements and growing demand for better diagnosis, are also discussed in the report.

Growth Path of the Immunoassay Interference Blocker Market

The evolution of immunoassay has brought substantial benefits in terms of analytical, operational, and clinical outcomes. The major types of immunoassay interference blockers have evolved back in the 1990s, but they became significant over the past fifteen years. The market for immunoassay interference blocker reagents and kits derived from Human serum or animal serum boomed over this age. Effective sales of immunoassay interference blocker including antibody interference blockers and detection interference blockers began in early 2000.

Over the years, immunoassay techniques have been the major highlighted products both in the diagnostic testing and proteomic research. More usage of immunoassay techniques in oncology research and high demand for immunoassay based testing were observed. The immunoassay interference blocker market is expected to generate a revenue of ~210 US$ Mn in 2019, and is expected to grow at a CAGR of ~6.5% over the period of forecast. Increased demand for new expertise and advancements in vitro diagnostics techniques have led to the growth of immunoassay interference blocker market.

The Impact of Undercurrents

Technological Advancements Push R&D capabilities

Manufacturing companies in immunoassay interference blocker market are concentrating on bringing new technologies and kits that could aid in effective diagnosis. This is expected to throw light on aggressiveness of progress of cancer and other viral and infectious diseases and expected patient survival period. Technological advancements aid in pushing the capabilities of research and development to bolster developments in immunoassay interference blocker market.

Rising Prevalence of Chronic Diseases

The rising incidences of chronic diseases along with the global increase in geriatric population is expected to increase the demand for diagnostic kits and reagents for the detecting age-related and other chronic conditions, which is expected to boost the immunoassay interference blocker market. Effective immunoassay interference blockers aid in improved diagnostics, thereby driving the product demand.

The market growth is going to be restricted by the lack of product awareness and increasing cost of immunoassay procedures in low and middle income countries. Along with this, owing to the low or poor detection limit, it will be a restraining factor for the growth of immunoassay interference blocker market.

Competitors’ Winning Strategies

Enhance R&D Efforts for New Products

High throughput quality research & development, along with the advancements in immune blockers for ensuring steady and high-performance quality will aid market as one of the fastest growing market in IVD products category with a healthy CAGR over the forecast period. Companies are focusing on improving their research and development activities to make therapies easier and safer for the users of biochemical testing products. Furthermore, the immunoassay interference blocker market is expected to be propelled by the increasing investments in research and development of molecular detection reagents.

Expand Detection Interference Blocker Portfolio

Although antibody interference blockers are expected to remain the sought-after product type, immunoassay interference blocker market competitors are expected to gain growth opportunities with the detection interference blocker portfolio which is likely to emerge as a high-growth variant during the period of forecast. Companies are expanding the detection interference blocker portfolio to capture a sizable share in the global market.

Corporate Tie-ups to Boost Distribution

Companies operating in the immunoassay interference blocker market continue to make efforts towards expanding their geographical footprint. Corporate tie-ups with domestic distributors enable them to extend their business across the lucrative regions, for providing Immunoassay Interference Blocker reagents to a larger consumer base. Increasing strategic collaborations and agreements among leading companies for manufacturing dual chamber prefilled syringe is expected to boost the revenue growth of the immunoassay interference blocker market.

Competitive Landscape Analysis

In May 2019, Roche Ltd. announced the worldwide launch of what the company claims to be the first and only in vitro diagnostic assay for ROS1 immunohistochemistry. The test identifies the ROS1 protein present in the tissue, and could be beneficial in recognizing ROS1-positive incidences of cancer.

In April 2019, Bio-Rad Laboratories, Inc., a leader of life science research and clinical diagnostic offerings, announced the grant of FDA clearance for its BioPlex 2200 Lyme Total Assay, which is an innovative multiplex test method to aid in the diagnosis of Lyme disease.

The immunoassay interference blocker market remains consolidated with leading players comprising of 65 to 70% share in the global market. Leading companies are emphasizing on expanding their position in the global market by means of new product development. Another vital strategy catalyzing growth of the immunoassay interference blocker market is the product diversification strategy. Primarily other players are focused on manufacturing Antibody Interference Blocker kits and reagents simultaneously, diversifying into other products. Manufacturers are focused on developing novel products with competitive pricing, thus expecting to increase their respective market shares.

Analysts’ Perspective of the Market

The PMR analysts’ have a positive perspective of the immunoassay interference blocker market.  The market has grown rapidly and has a major share in global diagnostics market. The growth of market is anticipated to increase significantly in the forecast period owing to increasing prevalence of chronic and other infectious disease. The increasing preference for low cost products are garnering competitors’ attention, wherein they aim to cater market demand. This is made possible with the help of technological advancements in production of interference blockers. New market entrants can imbibe similar strategies to gain market profitability. North America continues to remain the leading immunoassay interference blocker market owing to increasing demand of immunoassay interference blocker reagents and kits from biotechnology industry as well as academic and research institutes. Increasing molecular diagnosis, particularly in North American countries is likely to shape the future of the immunoassay interference blocker market in this region. Apart from this, East Asia is also expected to offer growth prospects to the immunoassay interference blocker market players, where major demand is created by academic and research institutes. Companies seeking opportunities in the immunoassay interference blocker market could consider East Asia for investments in the immunoassay interference blocker business.